My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1103

    1.

    Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.

    Ritzel R, Schulte M, Pørksen N, Nauck MS, Holst JJ, Juhl C, März W, Schmitz O, Schmiegel WH, Nauck MA.

    Diabetes. 2001 Apr;50(4):776-84.PMID: 11289042 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness.

    Juhl CB, Schmitz O, Pincus S, Holst JJ, Veldhuis J, Pørksen N.

    Diabetologia. 2000 May;43(5):583-8.PMID: 10855533 [PubMed - indexed for MEDLINE]Related articles

    3.

    Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.

    Pørksen N, Grøfte B, Nyholm B, Holst JJ, Pincus SM, Veldhuis JD, Schmitz O, Butler PC.

    Diabetes. 1998 Jan;47(1):45-9.PMID: 9421373 [PubMed - indexed for MEDLINE]Related articles

    4.

    Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.

    Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B.

    Diabetes. 1998 Aug;47(8):1259-65.PMID: 9703326 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

    Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA.

    J Clin Endocrinol Metab. 1996 Jan;81(1):327-32.PMID: 8550773 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

    Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, Schmiegel WH.

    J Clin Endocrinol Metab. 2002 Mar;87(3):1239-46.PMID: 11889194 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.

    Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.

    Diabetes. 2001 Aug;50(8):1778-84.PMID: 11473038 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Deconvolution analysis of rapid insulin pulses before and after six weeks of continuous subcutaneous administration of glucagon-like peptide-1 in elderly patients with type 2 diabetes.

    Meneilly GS, Veldhuis JD, Elahi D.

    J Clin Endocrinol Metab. 2005 Nov;90(11):6251-6. Epub 2005 Aug 9.PMID: 16091500 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

    Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

    Diabetes Care. 2003 Mar;26(3):791-8.PMID: 12610039 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

    Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.

    Diabetes Care. 2000 Jun;23(6):807-12.PMID: 10841001 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

    Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

    Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.PMID: 12189441 [PubMed - indexed for MEDLINE]Related articles

    13.

    Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

    Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W.

    Diabetes Care. 1998 Nov;21(11):1925-31.PMID: 9802745 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

    Diabetes Care. 1996 Jun;19(6):580-6.PMID: 8725855 [PubMed - indexed for MEDLINE]Related articles

    15.

    No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose.

    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

    Diabet Med. 2001 Feb;18(2):144-9.PMID: 11251679 [PubMed - indexed for MEDLINE]Related articles

    16.

    Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.

    Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M.

    Diabetologia. 2000 Jul;43(7):852-8.PMID: 10952457 [PubMed - indexed for MEDLINE]Related articles

    17.

    The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

    Kjems LL, Holst JJ, Vølund A, Madsbad S.

    Diabetes. 2003 Feb;52(2):380-6.PMID: 12540611 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

    Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

    Diabet Med. 1998 Nov;15(11):937-45.PMID: 9827848 [PubMed - indexed for MEDLINE]Related articles

    19.

    Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.

    Meier JJ, Kemmeries G, Holst JJ, Nauck MA.

    Diabetes. 2005 Jul;54(7):2212-8.PMID: 15983224 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

    J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity